1. |
2 Ricci F, Tedeschi A, Morra E,
et al
. Fludarabine in the treatment of chronic lymphocytic leukemia: a review.
Ther Clin Risk Manag
, 2009, 5(1): 187-207.
|
2. |
3 Wierda W, O'Brien S, Faderl S,
et al
. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Cancer
, 2006, 106(2): 337-345.
|
3. |
4 Hallek M, Fischer K, Fingerle-Rowson G,
et al
. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Lancet
, 2010, 376(9747): 1164-1174.
|
4. |
5 Eichhorst BF, Busch R, Hopfinger G,
et al
. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Blood
, 2006, 107(3): 885-891.
|
5. |
6 Grever MR, Lucas DM, Dewald GW,
et al
. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Journal of Clinical Oncology
, 2007, 25(7): 799-804.
|
6. |
8 Robak T, Dmoszynska A, Solal-Celigny P,
et al
. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia.
Journal of Clinical Oncology
, 2010, 28(10): 1756-1765.
|
7. |
9 Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Journal of Clinical Oncology
, 2007, 25(7): 793-798.
|
8. |
10 Dretzke J, Barton P, Kaambwa B,
et al
. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
Health Technol Assess
, 2010, 14(Suppl. 2): 19-26.
|
9. |
11 O'Brien S, Osterborg A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
Clin Lymphoma Myeloma Leuk
, 2010, 10(5): 361-368.
|
10. |
12 Byrd JC, Kipps TJ, Flinn IW,
et al
. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Blood
, 2010, 115(3): 489-495.
|
11. |
13 Wierda W, O'Brien S, Wen S,
et al
. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
J Clin Oncol
, 2005, 23(18): 4070-4078.
|
12. |
14 Casak SJ, Lemery SJ, Shen YL,
et al
. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Oncologist
, 2011, 16(1): 97-104.
|
13. |
16 Dohner H, Fischer K, Bentz M,
et al
. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
Blood
, 1995, 85 (6): 1580-1589.
|
14. |
17 Grever MR, Lucas DM, Dewald GW,
et al
. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
J Clin Oncol
, 2007, 25 (7): 799-804.
|
15. |
18 Dohner H, Stilgenbauer S, James MR,
et al
. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.
Blood
, 1997, 89(7): 2516-2522.
|
16. |
19 Tsimberidou AM, Tam C, Abruzzo LV,
et al
. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
Cancer
, 2009, 115(2): 373-380.
|
17. |
20 Schlette EJ, Admirand J, Wierda W,
et al
. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Leuk Lymphoma
, 2009, 50 (10): 1597-1605.
|
18. |
21 Moreno C, Villamor N, Colomer D,
et al
. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia.
J Clin Oncol
, 2005, 23 (15): 3433-3438.
|
19. |
顾卫军, 徐卫, 钱思轩, 等. 利妥昔单克隆抗体联合氟达拉滨及环磷酰胺治疗慢性淋巴细胞白血病. 中国实验血液学杂志, 2008, (04):938-942.
|
20. |
王欣, 刘林, 陈建斌, 等. 氟达拉滨联合环磷酰胺治疗慢性淋巴细胞白血病的临床研究. 重庆医学, 2009, 38(10): 1210-1212.
|
21. |
方成, 徐卫, 徐敏, 等. 氟达拉滨和环磷酰胺联合利妥昔单抗治疗慢性淋巴细胞白血病疗效分析. 中华血液学杂志, 2011, 32(1): 3-7.
|